Why People Stop Taking NMN (and the FDA NMN Saga)

Search "why I stopped taking NMN" and you'll find a recurring set of stories: people who didn't feel anything, people who balked at the price, and people who couldn't even buy it for a while because of a regulatory fight most consumers never understood. All three reasons are legitimate, and the third one — the FDA's on-again, off-again treatment of NMN — is one of the strangest episodes in the supplement world. Here's the honest version of both: what the science supports, and the full arc of how NMN went from acknowledged dietary ingredient, to delisted, to lawful again.

Reason 1: the benefits you can feel are hard to find

NMN (nicotinamide mononucleotide) is a precursor — a building block your cells convert into NAD+ (nicotinamide adenine dinucleotide), the coenzyme central to energy metabolism and DNA-repair enzymes ¹². The mechanistic story is genuine: NAD+ declines with age, and raising it is biologically plausible as a way to support cellular function ²³. That's why people start.

The problem is the gap between raising the biomarker and feeling different. NMN reliably does the first part. In a randomized, placebo-controlled trial in healthy middle-aged adults, oral NMN raised blood NAD+ in a dose-dependent way and was well tolerated ⁴; single-dose and 12-week safety studies found it was metabolized without meaningful adverse effects ⁵⁶. So if your only goal is "higher NAD+ on a blood test," NMN delivers.

The felt benefits are where it thins out. NMN's most-cited human result — improved muscle insulin sensitivity in prediabetic women — was narrow (most metabolic markers were unchanged) and was publicly contested by other researchers ⁷. Other trials report small, scattered, often subjective signals: maintained walking speed and self-reported sleep improvements in older adults ⁸, and a modest aerobic-capacity gain in amateur runners that the authors themselves tied to oxygen utilization rather than dramatic performance change ⁹. These are real enough to publish and far too modest to match the way NMN is marketed. For many people, "I took it for three months and felt nothing" is exactly what the evidence would predict. We unpack the broader hype-vs-evidence question in does NAD+ actually boost energy and what longevity research supports about NAD+ and anti-aging.

Reason 2: cost versus an uncertain payoff

NMN is not cheap, and a meaningful dose taken daily adds up over a year. When the expected benefit is "I might raise a biomarker whose felt effects are unproven," the math stops working for a lot of people. This isn't an anti-NMN argument so much as a rational one: the weaker the evidence for a felt benefit, the harder an ongoing expense is to justify. That calculation is a common, sensible reason to stop.

Reason 3: the FDA NMN saga — the part most people never understood

This is the differentiator, and it's worth telling in full because the headlines were confusing and often wrong.

Step 1 — NMN was an acknowledged dietary ingredient. For years, NMN was sold openly in the United States as a dietary supplement, and the FDA had even acknowledged new-dietary-ingredient notifications for it.

Step 2 — the 2022 reversal. On November 4, 2022, the FDA changed its position, stating that NMN is excluded from the legal definition of a dietary supplement. The basis was the "drug-preclusion" clause: an ingredient can be barred from the supplement category if it was first authorized for investigation as a new drug before being marketed as a supplement. NMN had become the subject of a pharmaceutical investigational-new-drug program (a NAD-boosting drug candidate), and the FDA invoked that to push NMN out of the supplement lane. Critics — including the Natural Products Association — argued this was the first time the agency had reversed itself on a dietary-ingredient acknowledgment without any new safety concern.

Step 3 — Amazon delisted it. Citing the FDA's action, Amazon told sellers they could offer NMN products only until March 13, 2023, after which NMN supplements were pulled from the platform. For many consumers, this is when NMN simply "disappeared," even though it was never illegal to possess and other retailers kept selling it.

Step 4 — the 2025 reversal of the reversal. In letters dated September 29, 2025, the FDA reconsidered and concluded that NMN is not excluded from the dietary-supplement definition after all. The reasoning turned on the "race-to-market" provision: the agency determined NMN had in fact been marketed as a supplement in the U.S. before the drug authorization, which preserves its eligibility as a dietary ingredient. NMN is lawful in supplements again, and products returned to major retailers.

The crucial takeaway: none of this back-and-forth was ever about whether NMN works or whether it's unsafe. It was a legal fight over which regulatory category NMN belongs in — driven by the timing of a drug-development program, not by trial data or a safety signal. If you stopped taking NMN because you thought the FDA had found it dangerous, that's a misreading; the agency's actions said nothing about efficacy or harm. (For the full legal status — including the EU and Australia picture — see is NMN legal? The FDA ban and 2025 reversal.)

A reason some people *switch* rather than stop: NR

A subset of people don't quit NAD+ precursors entirely — they move to nicotinamide riboside (NR), the other major oral precursor. Part of the appeal is regulatory: NR never went through NMN's exclusion drama, and chronic NR supplementation has its own controlled human data showing it reliably elevates NAD+ and is well tolerated ¹⁰. Whether NR's felt benefits are any better established than NMN's is a separate question — and the honest answer is that both share the same core limitation. We compare them directly in NMN vs NR: which precursor, and clear up the precursor-vs-molecule confusion in NMN vs NAD+: what's the difference. And if you're staying on NMN but want to buy more carefully, see how to choose an NMN supplement by evidence and purity.

What "should I stop?" actually comes down to

There's no medical reason most people must stop NMN — the safety data, while limited, has been reassuring at studied doses ⁵⁶. The honest decision framework is:

• •If you expected a felt benefit and got none, that's consistent with the evidence, and stopping is reasonable.
• •If the cost outweighs an unproven payoff for you, that's a sound reason too.
• •If you stopped because of the FDA "ban," know that NMN is lawful again as of late 2025, and the dispute was never about safety or efficacy.
• •If you have a health condition or take medications, decisions to start or stop any supplement are worth running past a clinician — NMN is a supplement, not an approved drug for any age-related or metabolic indication.

Bottom line

People stop taking NMN for three defensible reasons: the human benefits you can actually feel are thin and sometimes contested ⁷⁸⁹, the cost is hard to justify against that uncertainty, and the FDA's 2022 exclusion (followed by Amazon's March 2023 delisting) made it briefly unbuyable. That last reason has now reversed — the FDA declared NMN lawful again in September 2025 — but the reversal was a category dispute, not a verdict on whether NMN works. Raising NAD+ remains easy to claim and modest to prove. For the full picture, start with our NAD+ therapy evidence pillar and compare precursors on dose, form, and third-party testing on our NAD+ rankings hub.